Martin Babler, Alumis CEO
Immunology biotech Alumis secures $250M in shrunken IPO
Alumis, an immunology drug developer on the cusp of Phase 3, will go public Friday in a smaller IPO than it originally projected.
The Bay …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.